Although the small number of 50 study participants is a limiting factor, the samples available for this evaluation in patients with hormone receptor-positive breast cancer, are considered sufficient to support analytical validation and clinical utility of the BRCA 1.0 POC Research Assay as the primary aim achieved. Here, NR4A1 is linked to breast carcinoma.